Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCHEM1305


Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Principal Investigator(s)

Jonathan Irish


  • Protocol No. VICCHEM1305
  • Open Date: 04/02/2013
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective: To explore signaling and genetic factors that influence early and late responses to therapy in AML
  • Disease Sites: Leukemia
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCTNA
  • Secondary Protocol No: Not Specified


None Provided.


Not provided. Please call for more information.